Post-sustained Virologic Response Liver Stiffness May Underestimate Fibrosis After Direct Acting Antiviral-containing Therapy.
作者信息
Kardashian Ani, McKinney Jeff, Huynh Nina, Yu Robin, Peters Marion, Catalli Lisa, Price Jennifer C
机构信息
Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, University of California Los Angeles, University of California, San Francisco.
University of California San Francisco Medical Center, University of California, San Francisco.
出版信息
Clin Infect Dis. 2019 May 2;68(10):1784-1787. doi: 10.1093/cid/ciy951.
Abstract
摘要
相似文献
1
Post-sustained Virologic Response Liver Stiffness May Underestimate Fibrosis After Direct Acting Antiviral-containing Therapy.
Clin Infect Dis. 2019 May 2;68(10):1784-1787. doi: 10.1093/cid/ciy951.
2
Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
J Viral Hepat. 2020 Jan;27(1):28-35. doi: 10.1111/jvh.13204. Epub 2019 Oct 2.
3
Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):67-74. doi: 10.1097/MEG.0000000000001259.
4
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
World J Gastroenterol. 2020 Jun 7;26(21):2864-2876. doi: 10.3748/wjg.v26.i21.2864.
5
Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
Aliment Pharmacol Ther. 2018 Apr;47(7):1012-1022. doi: 10.1111/apt.14554. Epub 2018 Feb 9.
6
Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
World J Gastroenterol. 2018 Mar 21;24(11):1269-1277. doi: 10.3748/wjg.v24.i11.1269.
7
Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Endocr Metab Immune Disord Drug Targets. 2020;20(1):104-111. doi: 10.2174/1871530319666190826150344.
8
Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents.
Gastroenterol Hepatol. 2020 May;43(5):248-255. doi: 10.1016/j.gastrohep.2019.03.017. Epub 2020 Mar 16.
9
Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.
J Viral Hepat. 2018 Jul;25(7):802-810. doi: 10.1111/jvh.12879. Epub 2018 Mar 8.
10
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
Korean J Gastroenterol. 2018 Oct 25;72(4):197-204. doi: 10.4166/kjg.2018.72.4.197.
引用本文的文献
1
Correspondence to editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C".
Clin Mol Hepatol. 2025 Apr;31(2):e203-e205. doi: 10.3350/cmh.2025.0179. Epub 2025 Feb 24.
2
Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C".
Clin Mol Hepatol. 2025 Apr;31(2):658-661. doi: 10.3350/cmh.2025.0155. Epub 2025 Feb 17.
3
Liver stiffness in hepatocellular carcinoma and chronic hepatitis patients: Hepatitis B virus infection and transaminases should be considered.
World J Hepatol. 2024 Jul 27;16(7):1018-1028. doi: 10.4254/wjh.v16.i7.1018.
4
Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.
Blood Adv. 2023 Oct 10;7(19):5817-5824. doi: 10.1182/bloodadvances.2023010723.
5
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
J Korean Med Sci. 2019 Oct 28;34(41):e277. doi: 10.3346/jkms.2019.34.e277.
本文引用的文献
1
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. doi: 10.1093/cid/ciy585.
2
Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2018 Jan;16(1):27-38.e4. doi: 10.1016/j.cgh.2017.04.038. Epub 2017 May 4.
3
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
Gastroenterology. 2017 May;152(6):1544-1577. doi: 10.1053/j.gastro.2017.03.016.
4
Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
J Viral Hepat. 2016 Dec;23(12):994-1002. doi: 10.1111/jvh.12578. Epub 2016 Aug 8.
5
Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus-infected patients with a sustained virological response.
Aliment Pharmacol Ther. 2016 Aug;44(4):346-55. doi: 10.1111/apt.13695. Epub 2016 Jun 13.
6
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.
Hepatology. 2016 Jul;64(1):130-7. doi: 10.1002/hep.28535. Epub 2016 Apr 19.
7
A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
Clin Infect Dis. 2013 Jul;57(2):230-6. doi: 10.1093/cid/cit234. Epub 2013 Apr 24.
8
The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
J Hepatol. 2013 Aug;59(2):251-6. doi: 10.1016/j.jhep.2013.03.013. Epub 2013 Mar 23.
9
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
Zotero 插件